InstalabLoading...
InstalabLoading...
If you are already on a statin and your triglycerides remain elevated, your EPA (eicosapentaenoic acid) level tells you something that most standard lipid panels miss: whether you have enough of the specific omega-3 fatty acid shown to reduce heart attacks, strokes, and cardiovascular death on top of statin therapy. EPA is not just another omega-3. It has been tested more rigorously than any other fatty acid supplement, and the results separate it clearly from its better-known sibling, DHA.
EPA is a 20-carbon omega-3 fat found primarily in fatty fish and available in purified prescription form as icosapent ethyl. Your body cannot make much of it on its own, so your blood level largely reflects what you eat or supplement. What makes EPA unusual among nutritional molecules is that it has been studied in large, randomized, placebo-controlled trials, the same standard used for pharmaceutical drugs, and it passed.
The case for EPA rests primarily on a single, large trial called REDUCE-IT, which enrolled 8,179 adults already taking statins who had elevated triglycerides (median 216 mg/dL) and either established heart disease (about 71%) or diabetes with additional risk factors. Half received 4 grams per day of purified EPA; half received a placebo. After about 5 years, the EPA group had 25% fewer major cardiovascular events, including heart attacks, strokes, cardiovascular death, coronary procedures, and hospitalization for unstable chest pain (HR 0.75). The benefit was also clear for the harder endpoint of cardiovascular death, nonfatal heart attack, or nonfatal stroke, which was reduced by 26% (HR 0.74).
Cardiovascular death specifically was reduced by 20% (HR 0.80). That matters because many interventions lower nonfatal events without affecting mortality. In absolute terms, treating 1,000 people with high-dose EPA for 5 years prevented roughly 159 total ischemic events, with the largest contributions from fewer coronary procedures (76 events prevented), fewer heart attacks (42), and fewer strokes (14).
An earlier Japanese trial, JELIS, had already hinted at these benefits. Adding 1.8 grams per day of EPA to statin therapy reduced major coronary events by 19%, and the lowest event rates occurred in those who achieved the highest blood EPA concentrations. The benefit was most pronounced in people with triglycerides at or above 150 mg/dL and low HDL cholesterol.
A 2025 meta-analysis of 16 randomized trials covering nearly 128,000 people directly compared EPA alone against EPA/DHA combinations and found that purified EPA was superior for reducing cardiovascular death (HR approximately 0.79 for EPA alone versus 0.92 for EPA/DHA), even though the combined EPA/DHA group included far more participants across more trials.
What this means for you: if you are on a statin and still have triglycerides above 135 mg/dL, especially if you already have heart disease or diabetes with additional risk factors, high-dose purified EPA is one of the few add-on therapies proven to further reduce your cardiovascular risk. The benefit is not small, and it extends to the outcome that matters most: staying alive.
One of the most interesting findings from REDUCE-IT is that the cardiovascular benefit did not track with the degree of triglyceride lowering. People whose triglycerides dropped modestly got similar protection to those whose levels dropped substantially. This means the benefit is not simply about lower triglycerides. EPA appears to protect through several overlapping mechanisms.
EPA reduces the liver's production of triglyceride-rich particles (called VLDL), increases the rate at which your body clears fat from the bloodstream, and lowers levels of remnant cholesterol, a type of atherogenic particle that standard lipid panels often miss. At high doses, EPA typically lowers triglycerides by 20 to 30%. Unlike DHA, EPA does not raise LDL cholesterol, even when triglycerides are severely elevated. That distinction matters if your LDL is a concern.
Beyond lipids, EPA is converted into a family of molecules called resolvins that actively shut down inflammation. Think of inflammation as a fire: most anti-inflammatory drugs work by removing fuel, but resolvins act more like firefighters, actively resolving the damage. EPA also gets incorporated directly into the fatty plaques inside arteries. Imaging studies have shown that EPA-enriched plaques have less internal inflammation, less oxidative damage, and fewer of the immune cells that make plaques unstable and prone to rupturing, which is how most heart attacks begin.
EPA also has a more stable molecular structure than DHA, which allows it to resist oxidation in cell membranes and inhibit the oxidation of cholesterol. This structural difference may partly explain why EPA and DHA, despite both being omega-3 fats, produce different cardiovascular outcomes in trials.
EPA is generally well tolerated, but high-dose therapy comes with trade-offs you should understand before starting.
Atrial fibrillation: The most clinically important concern is a higher rate of atrial fibrillation (AF), an irregular heart rhythm originating in the upper chambers of the heart. In REDUCE-IT, AF occurred in 5.3% of the EPA group versus 3.9% of the placebo group, an absolute increase of 1.4%. Meta-analyses confirm this risk is dose-dependent, with a notably higher risk at doses above 1 gram per day (HR 1.49). If you have a history of AF or are at elevated risk, this trade-off deserves a careful conversation with your clinician.
Bleeding: EPA has mild antiplatelet effects, meaning it can make blood slightly less likely to clot. In the JELIS trial, total bleeding events were modestly higher with EPA (1.1% versus 0.6%). In REDUCE-IT, the difference approached but did not reach statistical significance (2.7% versus 2.1%). If you take blood thinners or antiplatelet medications, your clinician should monitor you more closely.
Minor side effects: Some people experience a fishy aftertaste, mild gastrointestinal symptoms like belching or nausea, or minor skin reactions. These occur in a small percentage and are rarely severe enough to stop the medication. Comprehensive meta-analyses have identified no definite serious adverse events caused by EPA. Despite being derived from fish oil, purified EPA products are highly refined and are not considered allergenic; people with seafood allergies can typically use them safely under medical guidance.
Your blood EPA level is driven almost entirely by dietary intake and supplementation, since your body converts very little EPA from plant-based omega-3 sources.
Dietary sources: Fatty fish such as salmon, mackerel, sardines, and anchovies are the richest natural sources. Two or more servings per week contribute meaningfully to EPA levels but will not approach the concentrations achieved with high-dose supplementation.
High-dose purified EPA (prescription): The dose studied in REDUCE-IT was 4 grams per day of icosapent ethyl. This is a prescription product, not a standard fish oil supplement. At this dose, triglycerides typically fall by 20 to 30%, with larger reductions in people with more severely elevated levels. In REDUCE-IT, median triglycerides dropped from 216 mg/dL to approximately 175 mg/dL. Current clinical guidelines from the American College of Cardiology (2021) and the American Association of Clinical Endocrinology (2025) recommend considering this therapy in statin-treated adults with LDL between 41 and 100 mg/dL and triglycerides between 135 and 499 mg/dL who have either established cardiovascular disease or diabetes with additional risk factors.
Standard-dose supplements: Over-the-counter fish oil capsules contain varying mixtures of EPA and DHA, typically at much lower doses. Meta-analyses suggest cardiovascular benefits are dose-dependent, with each additional 1 gram per day of combined EPA and DHA associated with approximately 9% lower heart attack risk and 7% lower total coronary heart disease risk. However, the strongest trial evidence supports purified EPA at prescription doses, not mixed EPA/DHA supplements.
What does not have strong evidence: There is currently insufficient evidence to recommend high-dose EPA for primary prevention in people without established cardiovascular disease or diabetes with risk factors. Only about 30% of REDUCE-IT participants fell into the primary prevention category, which limits how confidently the results can be applied to lower-risk populations.